OKENF - Rare Stock Picks In November 2023 - From 31 Discerning Analysts

2023-12-07 15:00:00 ET

Summary

• Welcome to another installment of our monthly Rare Stock Picks series. Today we're highlighting November 2023 investment picks you may have missed.
• As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment.
• Featured in this series are investment ideas published in the last month from analysts who have made ONLY 1 Buy/Strong Buy stock recommendation in the past three months.

November saw a relatively sustained market rally, and during the month some analysts presented their first Buy or Strong Buy recommendations in quite some time. Could these be of interest for your portfolio? Below is a list of November Buy recommendations made by analysts who had no other bullish recommendations over the past 3 months.

For your directory assistance, we've classified the opportunities by sector.

Materials

• Albemarle (ALB) - Analyst Cory Cramer presents their first buy recommendation in 6 months in choosing a contrarian opportunity on the large-cap chemical manufacturer. - I Recently Bought Albemarle And Here's My Strategy

• Crown Holdings (CCK) - This materials company, whose favor has ebbed and flowed throughout the years, is tipped as a good opportunity by Equanimity Investing following a nearly 40% pullback from its March 2022 highs. - Crown Holdings: Profit Recovery, Inexpensively Priced

Services

• BrightView Holdings (BV) - Commercial Landscape isn't a heavily trafficked investment area, but analyst Badsha Chowdhury , who's been issuing Hold ratings for months, found something he likes in Brightview. - BrightView Holdings: Recent Investment Inflow Can Change The Dynamics

Biotech

• Xenon Pharmaceuticals (XENE) - The Canadian clinical biotech in the neurological disorder space was cited by Edward Zhang as a potential opportunity with trial data releases pending. Shares have rallied since. - Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity

For further details see: